Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
QTTB
Strong BuyPremium GrowerQ32 Bio Inc. · Healthcare · United States · $447M · Avg Vol: $5M/d
89
StockRankGet insider-trade alerts
Q
87
V
36
M
65
P/E (TTM)
—
ROE
72.1%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.7M | -6.7M | 0 | 53.7M | 100.7% | 53.7M | 0.4M | 1.0M | -86.4% |
| EPS | -1.44 | -1.81 | -2.10 | 1.05 | — | — | — | — | — |
| Shares | 29.7M | 29.7M | 29.7M | 29.7M | 0.0% | 29.8M | — | — | — |
| Debt | 44.7M | 50.8M | 18.9M | 15.3M | -30.0% | 5.3M | — | — | — |
| Equity | -130.7M | -182.9M | 5.7M | 42.0M | 640.3% | — | — | — | — |
| Op CF | -11.0M | -18.7M | -67.7M | -33.5M | — | -19.8M | — | — | — |
| Inv CF | -2.5M | -5.0K | 19.9M | 7.0M | — | — | — | — | — |
| Fin CF | 30.1M | 0.4M | 95.1M | -3.1M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-31.1%
SMA 50SMA 200
Close
$10.72
RSI (14)
8.1
52W High
$23.57
From 52W High
0.5%
SCORE BREAKDOWN
Quality
87
ROIC
67.3%99.4
ROE
72.1%98.6
GP/Assets
63.8%92.4
Op. Margin
39.9%96.5
FCF/Assets
n/mN/A
Piotroski
559.7
Int. Cover
28.1x74.3
D/E Ratio
0.05x71.0
Current Ratio
20.30x96.0
Value
36
P/E (TTM)
—N/A
EV/EBITDA
11.7x61.1
P/FCF
n/mN/A
P/B
8.5x14.5
P/S
6.6x34.7
Div Yield
—N/A
Momentum
65
52W High %
45%22.3
RS 6M
42%95.3
SMA 50/200
1.82x99.8
EPS Rev 4W
+28.2%96.1
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$447M
P/E (Forward)
-11.8x
Gross Margin
73.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of QTTB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| QTTB | Q32 Bio Inc.(you) | $447M | 89 | Strong Buy |
| ZVRA | Zevra Therapeutics, Inc. | $687M | 91 | Strong Buy |
| PBYI | Puma Biotechnology, Inc. | $468M | 98 | Strong Buy |
| 1521.HK | Frontage Holdings Corporation | $310M | 93 | Strong Buy |
| CRMD | CorMedix Inc. | $647M | 98 | Strong Buy |
| AGEN | Agenus Inc. | $345M | 75 | Buy |
| ABUS | Arbutus Biopharma Corporation | $1.0B | 84 | Strong Buy |
| RIGL | Rigel Pharmaceuticals, Inc. | $868M | 99 | Strong Buy |
| PLX | Protalix BioTherapeutics, Inc. | $205M | 97 | Strong Buy |
| MDXG | MiMedx Group, Inc. | $656M | 73 | Buy |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%